You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePotassium
Accession NumberDB01345
TypeSmall Molecule
GroupsApproved
DescriptionPotassium is the major cation (positive ion) inside animal cells, while sodium is the major cation outside animal cells. The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential. The balance between potassium and sodium is maintained by ion pumps in the cell membrane. The cell membrane potential created by potassium and sodium ions allows the cell generate an action potential—a "spike" of electrical discharge. The ability of cells to produce electrical discharge is critical for body functions such as neurotransmission, muscle contraction, and heart function. Potassium is also an essential mineral needed to regulate water balance, blood pressure and levels of acidity.
Structure
Thumb
Synonyms
K
Kalium
Potassium alloy
UN1420
UN2257
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
K Lyte Cl Pwrpowder for solution1.86 goralBristol Labs Division Of Bristol Myers Squibb1965-12-311997-08-14Canada
Kali Sulph Tab 60mgtablet60 mgBiocentre1984-12-311997-05-30Canada
Kali Sulphuricumglobules; drops; liquid; granules; pellet; powder; tablet3 xCuranderos Ltd.1998-05-252002-11-20Canada
Polycitra-Ksolution398 mgoralJanssen Inc1996-12-312009-10-02Canada
Polycitra-Kpowder1.193 goralAlza Corporation1996-12-312001-08-01Canada
Potassium Acetateinjection, solution, concentrate196.3 mg/mLintravenousHospira, Inc.1984-07-20Not applicableUs
Potassium Acetateinjection, solution, concentrate3.93 g/20mLintravenousHospira, Inc.1984-07-20Not applicableUs
Potassium Acetateliquid392 mgintravenousSandoz Canada Incorporated1988-12-31Not applicableCanada
Potassium Acetate Inj 2meq/mlsolution2 meqintravenousAbbott Laboratories, Limited1984-12-312008-06-06Canada
Potassium Acetate Inj 392mg/ml USPliquid392 mgintravenousLyphomed, Division Of Fujisawa Canada Inc.1984-12-311996-09-10Canada
Potassium Acetate Injectionsolution392 mgintravenousFresenius Kabi Canada Ltd1984-12-31Not applicableCanada
Potassium Acetate Injection USPliquid39.2 %intravenousOmega Laboratories Ltd2016-07-18Not applicableCanada
Potassium Sulphate 7tablet6 xBiocentre1987-12-311997-05-30Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Potassium Acetateinjection, solution, concentrate3.93 g/20mLintravenousExela Pharma Sciences, Llc.2016-01-07Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Complexed Potassium Tablets - 99mgtablet99 mgoralAlbion Laboratories Inc.1996-09-062002-07-12Canada
K Lyte Tab Lime & Orange Flavtablet (effervescent)975 mgoralBristol Labs Division Of Bristol Myers Squibb1965-12-311997-08-14Canada
Port A Mins Super Potassium 99tablet99 mgoralGreat Earth Companies, Inc.1998-08-252002-10-02Canada
Potassium 250capsule250 mgoralSeroyal International Inc.1997-12-122009-07-06Canada
Potassium 99 - Caplettablet99 mgoralHealth Wise Nutrition Inc.1995-12-312002-07-18Canada
Potassium 99mg Tabletstablet99 mgoralBioforce Canada Inc.1994-12-311997-04-14Canada
Potassium Gluconate Tab 550mg USPtablet92 mgoralPharmavite Llc1991-12-312000-08-24Canada
Potassium Gluconate Tablets 99mg USPtablet99 mgoralRoyal Bodycare Canada Inc.1992-12-312001-08-07Canada
Potassium Rougierliquid780 mgoralRougier Pharma Division Of Ratiopharm Inc1965-12-312001-09-05Canada
Potassium Tab 99mgtablet99 mgoralDa Vinci Laboratories, Division Of Foodscience Corporation1981-12-311997-05-08Canada
Potassium Tab 99mgtablet99 mgoralRheingold Food International Ltd.1985-12-312007-07-26Canada
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Potassium Acetateinjection, solution196 mg/mLintravenousAmerican Regent, Inc.1990-09-30Not applicableUs
Potassium Acetateinjection, solution, concentrate392 mg/mLintravenousAmerican Regent, Inc.1990-09-30Not applicableUs
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
AlphaligoClinique Lafontaine Inc, Division Les Importations Ortho
AminosynHospira, Inc.
Aminosyn 3.5% MAbbott Laboratories, Limited
Aqua-S SupplementGarden State Nutritionals
B 6 PlusAnabolic Laboratories Inc.
BseltzerAbundance Marketing Ltd.
Buffered Vitamin C Powder With Ca Mg and KThorne Research Canada Ltd.
Buffered Vitamin C Pwr W Cal-mag-potassiumSisu Inc.
C-1000 Plus Zinc & PotassiumNu Life Nutrition Ltd.
C.R.D.-forcePrairie Naturals
Cal & Mag Hvp Chel Plus C Potass & Zinc TabGahler Enterprises Ltd.
Cal-mag (one To One) With Potass & ZincGahler Enterprises Ltd.
Cal-mag Plus K, Mn and Zn CapletsHealth Wise Nutrition Inc.
Calcium & Magnesium Citrate Plus D With Manganese, Potassium & ZincNatural Factors Nutritional Products Ltd.
Calcium & Magnesium Plus Potassium & ZincNatural Factors Nutritional Products Ltd.
Calcium & Magnesium Plus Potassium, Zinc, & ManganeseNatural Factors Nutritional Products Ltd.
Calcium & Magnesium With Potassium & ZincWn Pharmaceuticals Ltd.
Calcium & Magnesium With Potassium, Zinc, Manganese & Vitamin DWn Pharmaceuticals Ltd.
Calcium and Mag-potass and Zinc CapGahler Enterprises Ltd.
Calcium and Magnesium 1:1 Plus TabletsAlbi Naturals
Calcium Magnesium With Potassium TabNutrition For Life International
Calcium-magnesium With K & Zn and Vitamin D3Holista Health (Canada) Inc.
Chela Potassium PlusNu Life Nutrition Ltd.
Cmp PlexNutraceutical Corporation
Coenzyme Q10 Isotonix Vitamin and Mineral SupplementMarket America, Inc.
Complete Multivitamins and Minerals Tablets Timed ReleasePharmetics (2011) Inc
Dual MixOmnilife Manufactura, S.A. De C.V.
EnviveSisu Inc.
Extra P.N. Vitamin-mineral Drink MixChanges International
Flex CapsulesFoodscience Laboratories, Division Of Foodscience Corporation
Formula BPNutrivention Nutritional Products
Formula InfBalance Plus, Inc.
Formula JsNutrivention Nutritional Products
Formula R TabMetagenics, Inc.
Formula WbNutrivention Nutritional Products
Formule No 204 Profil TabPharmalab Inc.
Hi Potency B Complex W Chelated MineralsKlaire Labs Inc.
Hyperlyte (multi-electrolyte Concentrate)B. Braun Medical Inc
Hyperlyte CRB. Braun Medical Inc.
Hyperlyte CR Multi-electrolyte ConcentrateB. Braun Medical Inc
Hypo Vites TabPharmetics (2011) Inc
Iode-potassiumGamme Nature
Iodine-potassium TabletsLe Naturiste J.M.B. Inc.
Isotonix Advanced B-complex Vitamins With Potassium and MagnesiumMarket America, Inc.
Isotonix Calcium Plus FormulaMarket America, Inc.
Isotonix Vitamin B-folic Acid-mineral SuppleMarket America, Inc.
Kanga Sport Vitamins B & C Plus MineralsLacombe Drugs (1992) Ltd
Kenwood Liquid SupplementKenwood Laboratories (Division Of Bradley Pharmaceuticals)
Kmg PlusSeroyal International Inc.
LypholytePharmaceutical Partners Of Canada Inc
Lypholyte Multi-electrolyte Conc InjLyphomed, Division Of Fujisawa Canada Inc.
LyteprepTherapex Division De E Z Em Canada Inc
MagnacalHolista Health (Canada) Inc.
MgkHorizon SantÉ International Inc.
Multi Vitamins & MineralsWn Pharmaceuticals Ltd.
Multi-min Electro C Pow Plus B2Quest Vitamins A Div Of Purity Life Health Products
Multi-vitamins With MineralsWn Pharmaceuticals Ltd.
Multimineral ChelatesW.R. Enterprises Inc.
Normosol M With Dextrose 5%Hospira Healthcare Corporation
Normosol-M and DextroseHospira, Inc.
Nutrilite Double XNutrilite, A Division Of Access Business Group, Llc
NutrilyteAmerican Regent, Inc.
Nutrilyte IIAmerican Regent, Inc.
OnccorSimone Protective Pharmaceuticals, Inc.
One A Day Advance AdultsBayer Inc Consumer Care
One A Day Advance Adults 50+Bayer Inc Consumer Care
One A Day TabCountry Health Laboratories Ltd.
Orange Flavored Crystal Chews TabJeunique International Inc.
Osteo FormulaGeneral Nutrition Canada Inc.
Plasma-lyte 56 5% Dextrose InjBaxter Corporation
Plasma-lyte 56 and DextroseBaxter Healthcare Corporation
Potassium and Iodine TabAlbi Naturals
Q-10 PlusThorne Research Inc.
Spectra 301 Vitamin and Mineral SuppNf Formulas Inc.
Spectrum 2 CapNf Formulas Inc.
Super C-M-KCreative Nutrition Canada Corp.
Super Charged EnergySimone Protective Pharmaceuticals, Inc.
Super Daily No 2W.R. Enterprises Inc.
Super-cellBody Wise International Llc
Suprep Bowel PrepBraintree Laboratories, Inc.
Tar-endNature's Sunshine Products Inc.
Tri-mins - CapAlbion Laboratories Inc.
Twin Ultra Liquid Fruit Punch FlavorTwin Laboratories Inc.
Twin Ultra Liquid Grape FlavorTwin Laboratories Inc.
Twin Ultra Liquid Lemon-lime FlavorTwin Laboratories Inc.
Twin Ultra Liquid Orange FlavorTwin Laboratories Inc.
Vimeral TabIcn Canada Ltd.
Vit C W Calc-mag and Potass PowderNf Formulas Inc.
Vitalife - CapsuleHolista Health (Canada) Inc.
Women's FormulaPro Ma Systems
Z-force Vitamin and Mineral SupplementDymatize Enterprises Inc.
Z-mass PM Vitamin and Mineral SupplementCytodyne Technologies Inc.
Salts
Name/CASStructureProperties
Potassium acetate
ThumbNot applicableDBSALT001427
Potassium sulfate
ThumbNot applicableDBSALT001465
Categories
UNIIRWP5GA015D
CAS number7440-09-7
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Taxonomy
ClassificationNot classified
Pharmacology
IndicationPotassium is used to regulate hypokalemia as a primary condition or secondary to other medical conditions.
PharmacodynamicsNot Available
Mechanism of actionPotassium is the major cation (positive ion) inside animal cells, while sodium is the major cation outside animal cells. The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential. The balance between potassium and sodium is maintained by ion pumps in the cell membrane. The cell membrane potential created by potassium and sodium ions allows the cell generate an action potential—a "spike" of electrical discharge. The ability of cells to produce electrical discharge is critical for body functions such as neurotransmission, muscle contraction, and heart function. Potassium is also an essential mineral needed to regulate water balance, blood pressure and levels of acidity.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationMostly urine but also skin and feces.
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
Pathways
PathwayCategorySMPDB ID
Pyruvate MetabolismMetabolicSMP00060
Indapamide Action PathwayDrug actionSMP00110
Trichlormethiazide Action PathwayDrug actionSMP00121
Amiloride Action PathwayDrug actionSMP00133
Rabeprazole Action PathwayDrug actionSMP00229
Alprenolol Action PathwayDrug actionSMP00297
Quinidine Action PathwayDrug actionSMP00323
Lidocaine (Antiarrhythmic) Action PathwayDrug actionSMP00328
Tocainide Action PathwayDrug actionSMP00330
Ibutilide Action PathwayDrug actionSMP00332
Methylenetetrahydrofolate Reductase Deficiency (MTHFRD)DiseaseSMP00340
Diltiazem Action PathwayDrug actionSMP00359
Lesch-Nyhan Syndrome (LNS)DiseaseSMP00364
Labetalol Action PathwayDrug actionSMP00368
Verapamil Action PathwayDrug actionSMP00375
Amlodipine Action PathwayDrug actionSMP00376
Nimodipine Action PathwayDrug actionSMP00380
Levobupivacaine Action PathwayDrug actionSMP00397
Oxymorphone Action PathwayDrug actionSMP00412
Fentanyl Action PathwayDrug actionSMP00415
Fluoxetine Action PathwayDrug actionSMP00426
Nicotine Action PathwayDrug actionSMP00431
Spermidine and Spermine BiosynthesisMetabolicSMP00445
Lactose DegradationMetabolicSMP00457
Myoadenylate deaminase deficiencyDiseaseSMP00537
Pyruvate kinase deficiencyDiseaseSMP00559
Levorphanol Action PathwayDrug actionSMP00673
Anileridine Action PathwayDrug actionSMP00674
Methadyl Acetate Action PathwayDrug actionSMP00678
Buprenorphine Action PathwayDrug actionSMP00684
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal AbsorptionNot AvailableNot Available
Blood Brain BarrierNot AvailableNot Available
Caco-2 permeableNot AvailableNot Available
P-glycoprotein substrateNot AvailableNot Available
P-glycoprotein inhibitor INot AvailableNot Available
P-glycoprotein inhibitor IINot AvailableNot Available
Renal organic cation transporterNot AvailableNot Available
CYP450 2C9 substrateNot AvailableNot Available
CYP450 2D6 substrateNot AvailableNot Available
CYP450 3A4 substrateNot AvailableNot Available
CYP450 1A2 substrateNot AvailableNot Available
CYP450 2C9 inhibitorNot AvailableNot Available
CYP450 2D6 inhibitorNot AvailableNot Available
CYP450 2C19 inhibitorNot AvailableNot Available
CYP450 3A4 inhibitorNot AvailableNot Available
CYP450 inhibitory promiscuityNot AvailableNot Available
Ames testNot AvailableNot Available
CarcinogenicityNot AvailableNot Available
BiodegradationNot AvailableNot Available
Rat acute toxicityNot AvailableNot applicable
hERG inhibition (predictor I)Not AvailableNot Available
hERG inhibition (predictor II)Not AvailableNot Available
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsuleoral
Tabletoral
Tablet (extended-release)oral
Injection, solution, concentrateintravenous
Liquidintravenous
Powderoral
Powder for solutionoral1.86 g
Tablet (effervescent)oral975 mg
Tablet60 mg
Globules; drops; liquid; granules; pellet; powder; tablet3 x
Tablet (effervescent)oral
Powder (effervescent)oral
Solutionintravenous
Injection, solutionintravenous
Powderoral1.193 g
Solutionoral398 mg
Capsuleoral250 mg
Injection, solutionintravenous196 mg/mL
Injection, solution, concentrateintravenous196.3 mg/mL
Injection, solution, concentrateintravenous3.93 g/20mL
Injection, solution, concentrateintravenous392 mg/mL
Liquidintravenous392 mg
Solutionintravenous2 meq
Solutionintravenous392 mg
Liquidintravenous39.2 %
Tabletoral92 mg
Tabletoral99 mg
Liquidoral780 mg
Tablet6 x
Solution, concentrateoral
Liquidoral
Powder for solutionoral
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6946149 No2003-03-072023-03-07Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point63.38 °CNot Available
boiling point770°CNot Available
water solubilitySolubleNot Available
Predicted PropertiesNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
References
Synthesis Reference

John B. Sardisco, “Production of potassium sulfate and hydrogen chloride.” U.S. Patent US4045543, issued 1865.

US4045543
General ReferencesNot Available
External Links
ATC CodesC03BB07C03AB04C03AB02C03CB02C03AB03C03AB06C03AB07C03AB05C03AB01B05XA17C03BB04C03BB03C03CB01C03AB08C03BB02C03AB09C03BB05
AHFS Codes
  • 40:12.00
  • 40:28.92
  • 40:34.00*
  • 68:36.08
  • 84:92.00
  • 88:29.00*
  • 92:00.00
  • 92:02.00*
PDB EntriesNot Available
FDA labelDownload (632 KB)
MSDSDownload (72.2 KB)
Interactions
Drug Interactions
Drug
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Potassium.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Potassium.
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Potassium.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Potassium.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Potassium.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Potassium.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Potassium.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Potassium.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Potassium.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Potassium.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Potassium.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Potassium.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Potassium.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Potassium.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Potassium.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Potassium.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Potassium.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Potassium.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Potassium.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Potassium.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Potassium.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Potassium.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Potassium.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Potassium.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Potassium.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Potassium.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Potassium.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Potassium.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Potassium.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Potassium.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Potassium.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Potassium.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Potassium.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Potassium.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Potassium.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Potassium.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Potassium.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Potassium.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Potassium.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Steroid hormone binding
Specific Function:
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients.
Gene Name:
ATP1A1
Uniprot ID:
P05023
Molecular Weight:
112895.01 Da
References
  1. Silva E, Gomes P, Soares-da-Silva P: Overexpression of Na(+)/K (+)-ATPase parallels the increase in sodium transport and potassium recycling in an in vitro model of proximal tubule cellular ageing. J Membr Biol. 2006;212(3):163-75. Epub 2007 Feb 28. [PubMed:17334838 ]
  2. Li C, Geering K, Horisberger JD: The third sodium binding site of Na,K-ATPase is functionally linked to acidic pH-activated inward current. J Membr Biol. 2006;213(1):1-9. Epub 2007 Mar 8. [PubMed:17347782 ]
  3. Stanely Mainzen Prince P, Karthick M: Preventive effect of rutin on lipids, lipoproteins, and ATPases in normal and isoproterenol-induced myocardial infarction in rats. J Biochem Mol Toxicol. 2007;21(1):1-6. [PubMed:17366541 ]
  4. Simon WA, Herrmann M, Klein T, Shin JM, Huber R, Senn-Bilfinger J, Postius S: Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther. 2007 Jun;321(3):866-74. Epub 2007 Mar 16. [PubMed:17369284 ]
  5. Iannello S, Milazzo P, Belfiore F: Animal and human tissue Na,K-ATPase in normal and insulin-resistant states: regulation, behaviour and interpretative hypothesis on NEFA effects. Obes Rev. 2007 May;8(3):231-51. [PubMed:17444965 ]
Comments
comments powered by Disqus
Drug created on June 30, 2007 12:13 / Updated on September 26, 2016 02:14